Responding to NHS Change for Pharma UK Summit

eyeforpharma1st-2nd July 2008
eyeforpharma has announced two thirds of it's speakers line-up for the UK's most influential strategic conference for the pharmaceutical industry on 1-2 July in London. The conference is yet to be officially launched but in a sneak preview of the agenda Gerard Moore has announced that the following UK experts will be speaking at the event.

In a statement Mr Gerard Moore said: "We are so proud to be part of this ongoing improvement of pharma's strategies to the UK market, their conduct and their success in generating top-line revenue for the industry. With the UK healthcare environment producing so many new challenges and dynamic changes, sales and marketing activities in pharmaceutical companies need to really start responding to this healthcare climate change. This conference provides a perfect learning, knowledge sharing and discussion platform to overcome these challenges"

The Keynotes include:

  • Richard McMahon, Clinical Director, Virgin Healthcare
  • Dudley Ferguson, Managing Director, Astellas
  • Martin Anderson, Director of NHS Policy Partnerships, ABPI
  • Peter Rowe, Chief Executive, Ashton, Wigan & Leigh PCT
  • Martin Symons, General Manager, Recordati

And the rest are now available to see on the official website www.eyeforpharma.com/uk08

In addition, eyeforpharma proudly announce an exclusive pre-Conference 1 Day workshop dedicated to Key Account Management in the UK Pharma Industry.

The event is the 2nd annual event for the pharmaceutical industry and was a huge success last year when it brought together over 120 senior-level pharmaceutical executives and healthcare stakeholders such as the ABPI, PCTs, the National Association of Primary Care and The Royal Pharmaceutical Society of Great Britain and discuss how to pharmaceutical companies can respond better to changes in the NHS and what they should be doing in order to meet their needs.

eyeforpharma is offering a special pre-launch discount for those that register their place at the Conference early, with £200 knocked off the price of tickets to anyone registering before April 18th.

Further updates, full information on presentations and speakers, and details on other ticket options can all be found by visiting www.eyeforpharma.com/uk08

The event is organised and researched independently by eyeforpharma.

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. eyeforpharma reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...